表紙
市場調查報告書

7個主要國家/地區基於新抗原的個別化癌症治療疫苗市場:到2035年的競爭情況和市場預測

Neoantigen-based Personalized Cancer therapeutic Vaccines-Competitive Landscape and Market Forecast-by 2035

出版商 DelveInsight Business Research LLP 商品編碼 954177
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
7個主要國家/地區基於新抗原的個別化癌症治療疫苗市場:到2035年的競爭情況和市場預測 Neoantigen-based Personalized Cancer therapeutic Vaccines-Competitive Landscape and Market Forecast-by 2035
出版日期: 2020年04月01日內容資訊: 英文 150 Pages
簡介

癌症疫苗旨在增強對癌症的免疫反應,使免疫系統能夠識別,攻擊和破壞癌細胞。由癌症特異性突變產生的新抗原(腫瘤特異性抗原)源自腫瘤細胞中的隨機體細胞突變,在正常細胞中不存在。這使得新抗原不同於非突變自身抗原,很可能會被宿主免疫系統識別為非自身抗原,從而使其成為高度特異性,有效且安全的免疫療法的有吸引力的靶標。對腫瘤特異性新抗原有反應的疫苗可以最大程度地降低誘導中樞和外周耐受性以及自身免疫風險的可能性,基於新抗原的癌症疫苗可以用於臨床前和早期臨床試驗。兩者都顯示出巨大的潛力。

此報告涵蓋美國,德國,法國,意大利,西班牙,英國和日本。 對7個主要國家/地區的基於新抗原的個性化癌症治療疫苗市場進行的調查,以提供有關競爭狀況,市場概況,需求未滿足,新療法,市場分析和前景的信息

目錄

第1章主要發現

第2章執行摘要

第3章競爭信息分析

第4章市場概述

  • 每個地區的市場佔有率
  • 按市場佔有率

第5章基於新抗原的個性化癌症治療疫苗

  • 簡介
    • 腫瘤新抗原:從基礎研究到臨床應用
    • 腫瘤新抗原研究的歷史回顧
    • 新抗原引導的免疫編輯和免疫逃避
    • 臨床前和臨床研究概述
    • 新抗原的鑑定和預測
    • 新抗原疫苗原理
    • 臨床研究進展
    • 利弊

第6章不受支持的需求

第7章新療法

  • 主要競爭對手產品
  • Tedopi(OSE2101):OSE免疫治療藥
    • 產品概述
    • 其他發展活動
    • 臨床發展
    • 安全性和有效性
    • 產品簡介
  • GRANITE(GRT-C901)+ SLATE(GRT-R902):Gritstone Oncology
  • GEN-009 Adjuvanted Vaccine:Genocea Biosciences
  • TG01 Vaccine:Targovax
  • iNeo-Vac-P01:Hangzhou Neoantigen Therapeutics
  • NEO-PV-01:Neon Therapeutics

第8章主要7個國家的市場分析

  • 主要發現
  • 7個主要國家的市場規模

第9章7個主要國家/地區:市場前景

  • 美國:市場規模
    • 總體市場規模
    • 按治療方法劃分的市場規模
  • 五個歐洲國家:市場規模和前景
    • 總體市場規模
    • 按治療方法劃分的市場規模
  • 日本市場前景
    • 總體市場規模
    • 按治療方法劃分的市場規模

第10章屬性分析

第11章主要專家的觀點

第12章市場增長動力

第13章市場壁壘

第14章未來展望

第15章附錄

  • 參考
  • 報告調查方法

第16章DelveInsight的服務內容

第17章免責聲明

第18章:關於Delve Insight

目錄
Product Code: DICL0012

DelveInsight's 'Neoantigen-based Personalized Cancer therapeutic Vaccines-Competitive Landscape and Market Forecast-by 2035' report delivers an in-depth understanding of the Neoantigen based Personalized Cancer therapeutic Vaccines and the Neoantigen-based personalized cancer therapeutic vaccines emerging market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: by 2035.

Neoantigen-based Personalized Cancer therapeutic Vaccines Understanding

Neoantigen-based Personalized Cancer therapeutic Vaccines Overview

Cancer vaccines use weakened or killed viruses, bacteria, or other infection-causing agents to initiate an immune response in the body. These vaccines are designed to work similarly, wherein the immune system will recognize, attack, and destroy cancer cells. They identify cancer cells as foreign, and therefore, prepare the immune system to attack the cancer cells. Cancer vaccines are one way to utilize the body's immune system to fight cancer.

Neoantigens that arise from cancer-specific mutations represent another class of attractive antigens for therapeutic cancer vaccines. Vaccination against the tumor-specific neoantigens minimizes the potential induction of central and peripheral tolerance as well as the risk of autoimmunity. Neoantigen-based cancer vaccines have recently showed marked therapeutic potential in both preclinical and early-phase clinical studies.

Tumor-specific antigens, also termed as neoantigens, are derived from random somatic mutations in tumor cells and not present in normal cells. Compared to those non-mutated self-antigens, neoantigens could be recognized as non-self by the host immune system and are thus attractive targets for immunotherapies with potentially increased specificity, efficacy, and safety.

Tumor vaccines that target neoantigens mainly include nucleic acid, dendritic cell (DC)-based, tumor cell, and synthetic-long peptide (SLP) vaccines. The combination with immune checkpoint inhibition therapy or radiotherapy and chemotherapy might achieve better therapeutic effects. Currently, several clinical trials have demonstrated the safety and efficacy of these vaccines. Neoantigen-related immunotherapy is a truly personalized therapy because most neoantigens are derived from unique mutations in each tumor genome. Therefore, identification of patient-specific immunogenic neoantigens is the first step in developing such personalized vaccines.

Key Findings

The total Market size of Neoantigen-based Personalized Cancer therapeutic Vaccines for Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Urothelial Carcinoma, Cutaneous Melanoma, Renal Cell Carcinoma along with few other indications were determined for calculating the market size of several vaccines in the 7MM countries by 2035.

Neoantigen-based Personalized Cancer therapeutic Vaccines Emerging Therapies Chapters

This segment of the Neoantigen-based Personalized Cancer therapeutic Vaccines report encloses its detailed analysis of various vaccines in different stages of clinical development, including phase III, I/II, and I. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included vaccine, and the latest news and press releases.

Neoantigen-based Personalized Cancer therapeutic Emerging Vaccines

Tedopi (OSE2101): OSE Immunotherapeutics

OSE Immunotherapeutics' lead clinical immune-oncology asset is Tedopi, which is neoantigen-based immunotherapy in development for the treatment of HLA-A2+ NSCLC. It contains a combination of 10 optimized neo-epitopes, which are parts of proteins that structurally alter cancer cells and trigger strong immune responses against them. The epitopes present in Tedopi are optimized from five tumorous antigens. The epitopes express a minimum of one of the tumor antigens and generate a specific response from cytotoxic (aka killer) T-cells against cancer cells. Tedopi works by stimulating killer T-cells, enabling them to spot and eliminate cancerous cells, which is a key process in the treatment of disease. Currently, the vaccine is in phase III stage of clinical development for Non-small Cell Lung Cancer.

GRANITE (GRT-C901) + SLATE (GRT-R902): Gritstone Oncology

Gritstone Oncology is developing a combination vaccine product; wherein, GRANITE is personalized neoantigen-based immunotherapy. It is engineered to elicit a significant T-cell response (particularly CD8+ cytotoxic T-cells) against mutation-derived tumor-specific neoantigens, or TSNA, identified for each patient through the company's proprietary EDGE machine learning-based platform. It consists of two components, first an adenoviral priming vector followed by monthly boosting with an RNA vector, each containing the same 20 patient-specific TSNA. On the other hand, SLATE will utilize the same antigen delivery system as GRANITE but includes a fixed set of neoantigens that are shared across a subset of cancer patients rather than neoantigens unique to an individual patient, providing with an off-the-shelf alternative to GRANITE. Currently, the vaccine combination is in phase I/II stage of clinical development for multiple cancer indications such as Colorectal Cancer, Urothelial Carcinoma, and others.

GEN-009 Adjuvanted Vaccine: Genocea Biosciences

GEN-009 is a personalized cancer vaccine that uses Genocea's proprietary ATLAS platform to optimize target selection so that the vaccine has the best chance of targeting the right tumor mutations in each person. It is an adjuvanted neoantigen peptide vaccine candidate designed to direct a patient's immune system to attack their tumor. Currently, the vaccine is in phase I/II stage of clinical development for multiple cancer indications, such as Cutaneous Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Urothelial Carcinoma, and Renal Cell Carcinoma.

TG01 Vaccine: Targovax

TG01 is a Neoantigen-specific peptide vaccine targeting RAS mutations-that result in uncontrolled cell divisions-in solid tumors being developed by Targovax. It has developed a unique vaccine against mutant RAS. Upon intradermal administration, TG01 peptides are taken up by activated dendritic cells that migrate to lymph nodes where DCs present the peptides to T cells. Subsets of T cells learn to recognize (CD4+ T helper cells directly and CD8+ Cytotoxic T cells by cross-presentation) the RAS mutations and enter the circulation of the body. When encountering cancer cells with RAS mutations, the T cells are re-activated to generate and trigger immunological killing of the cancer cells. Currently, the vaccine has completed phase I/II stage of clinical development for Pancreatic Cancer.

iNeo-Vac-P01: Hangzhou Neoantigen Therapeutics

iNeo-Vac-P01 by Hangzhou Neoantigen Therapeutics is a peptide-based, personalized cancer vaccine consisting of patient-specific mutated long peptides, which are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. Upon vaccination with the personalized neoantigen peptide vaccine iNeo-Vac-P01, the peptides stimulate the host immune system to mount a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. Currently, the vaccine is in phase I stage of clinical development for advanced malignant solid tumor such as Pancreatic Carcinoma.

NEO-PV-01: Neon Therapeutics

NEO-PV-01 is a fully personalized cancer vaccine targeting neoantigens that are custom-designed and manufactured for each individual patient based upon the tumor's unique mutational fingerprint. The neoantigen-targeting peptides in NEO-PV-01 are intended to generate an antitumor immune response that directs patients' T-cells to target and kill their cancer cells. NEO-PV-01 is being studied in multiple ongoing phase I clinical trials for Urinary Bladder Cancer, Non-small Cell Lung Cancer, and Metastatic Melanoma.

Neoantigen-based Personalized Cancer therapeutic Vaccines Therapeutic Assessment

This segment of the report provides insights about the different emerging vaccines segregated based on following parameters that define the scope of the report, such as:

  • Major Key Players
  • Phases
  • Route of Administration
  • Target Indications of various Vaccines

Neoantigen-based Personalized Cancer therapeutic Vaccines: Market Outlook

The Neoantigen-based Personalized Cancer therapeutic Vaccines market outlook of the report helps in building the detailed understanding of the forecasted Cancer therapeutic Vaccines market by analyzing the therapeutic vaccines based on its promising safety and efficacy results, extent of T-cell responses, tolerability, extent of tumor reduction, extent of recurrence reduction, improvement in median overall survival rate, improvement in progression free survival rate, degree of overcoming unmet needs, market drivers and barriers along with promising novel technologies.

This segment gives a thorough understanding of Neoantigen-based personalized cancer therapeutic vaccines market trend of each pipeline emerging vaccine by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Neoantigen-based Personalized Cancer Therapeutic Vaccines market in 7MM is expected to change in the study period by 2035.

Key Findings

This section includes a glimpse of the Neoantigen-based Personalized Cancer Therapeutic Vaccines market in 7MM.

The United States Market Outlook

This section provides the total Neoantigen-based Personalized Cancer Therapeutic Vaccines market size along with market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Neoantigen-based Personalized Cancer Therapeutic Vaccines market size along with market size by therapies in EU5 Countries is provided in this section.

Japan Market Outlook

The total Neoantigen-based Personalized Cancer Therapeutic Vaccines market size along with market size by therapies in Japan is provided.

Neoantigen-based Personalized Cancer Therapeutic Vaccines Uptake

This section focusses on the emerging vaccines of the Neoantigen-based Personalized Cancer Therapeutics, which will get launched in the market during the study period by 2035. The analysis covers Neoantigen-based Personalized Cancer Therapeutic Vaccines market, patient uptake by therapies, and sales of each vaccine.

This helps in understanding the vaccines with the most rapid uptake, reasons behind the maximal use of new vaccines, and allows the comparison of the vaccines on the basis of market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Neoantigen-based Personalized Cancer therapeutic Vaccines Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, and Phase I/II stage. It also analyses Neoantigen-based Personalized Cancer Therapeutic Vaccines key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of Neoantigen-based Personalized Cancer therapeutic Vaccines emerging therapies.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Neoantigen-based Personalized Cancer therapeutic Vaccines domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform competitive and market intelligence analysis of the Neoantigen-based Personalized Cancer Therapeutic Vaccines Market by using various tools that include SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Neoantigen-based Personalized Cancer therapeutic Vaccines.
  • Comprehensive insight has been provided into the Neoantigen-based Personalized Cancer therapeutic Vaccines for several cancer indications and treatment in the 7MM.
  • Additionally, an all-inclusive account of emerging vaccines for Neoantigen-based Personalized Cancer therapeutic Platform are provided, along with the assessment of new therapies, which will have an impact on the market.
  • A detailed review of Neoantigen-based Personalized Cancer therapeutic Vaccines market; forecasted is included in the report, covering vaccine outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Neoantigen-based Personalized Cancer Therapeutic Vaccines market.

Report Highlights:

  • There are 10+ active players involved in developing therapies for Neoantigen-based Personalized Cancer therapeutic Vaccines. Launch of emerging vaccines will significantly impact the Neoantigen-based Personalized Cancer therapeutic Vaccines market.
  • Apart from the main company, several collaborators are also actively working to develop these potential and promising cancer vaccines. There are approximately 10+ companies involved in licensing agreements and collaborations for the development and commercialization of these vaccines.
  • Expected launch of 15+ potential Neoantigen-based Personalized Cancer therapeutic Vaccines will increase the market size in the coming years, assisted by an increase in diagnosed incident population of several cancer indications along with advancements in treatment options, which makes it clear that the upcoming cancer vaccine are majorly expected to boom the overall therapeutic market in the oncology sector by acting as an adjuvant therapy to the already existing Standard of care therapies (SOC).
  • The increase in market size is also expected due to the rising awareness regarding the current unmet need for adjuvant therapies, along with incremental healthcare spending across the world, which would expand the size of the market to enable the vaccine manufacturers to penetrate more into the market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Neoantigen-based Personalized Cancer therapeutic Vaccines.
  • A section comprising of vaccine types, which will include neo-antigen based mRNA vaccines, neo-antigen based Viral/Bacterial vaccines, neo-antigen based polypeptide vaccines, neo-antigen based Dendritic cell vaccines along, immunotherapy based vaccines along with allogeneic and autologous tumor cell based neo-antigen vaccines.
  • The report also provides detailed attribute analysis of individual vaccines based on several uniform parameters such safety , efficacy, tolerability, extent of T-cell responses, extent of tumor reductions, extent of recurrence reduction, median overall survival(MOS), progression free survival (PFS) grade level toxicity, company funding's and collaborations
  • The companies, universities and associations are working together to assess challenges and seek opportunities that could influence Neoantigen-based Personalized Cancer therapeutic Vaccines R&D.
  • These Neoantigen-based Personalized Cancer therapeutic Vaccines are being developed based on novel technology platforms approaches, will help advance precision medicine using Improved high-throughput technologies, which are providing feasible tools for analyzing the mutation antigen profile, the gene signature and epigenetic modification of tumor and immune cells, as well as the magnitude, homing capacity, cytotoxic function and T cell receptor (TCR) repertoire of T lymphocytes.
  • Detailed SWOT Analysis
  • Detailed Therapeutic Assessment, which will include the assessment of vaccines by Major Key Players, by Phases, by Vaccine types, by route of administration, and target or primary indication.
  • Our in-depth analysis of the pipeline assets across different stages of development, different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, expected launch dates along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Neoantigen-based Personalized Cancer therapeutic Vaccines Report Insights

  • Neoantigen-based Personalized Cancer therapeutic Vaccines Pipeline Analysis
  • Neoantigen-based Personalized Cancer therapeutic Vaccines Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Vaccines

Neoantigen-based Personalized Cancer therapeutic Vaccines Report Key Strengths

  • Forecast till 2035
  • 7MM Coverage
  • Neoantigen-based Personalized Cancer therapeutic Vaccines Segmentation based on Various Cancer Indications
  • Key Cross Competition
  • Highly Analyzed Market
  • Vaccines Uptake
  • Detailed therapeutic Assessment

Neoantigen-based Personalized Cancer therapeutic Vaccines Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT Analysis
  • Attribute Analysis

Key Questions:

Market Insights:

  • What is the expected Neoantigen-based Personalized Cancer therapeutic Vaccines 7MM Market share (%) in 2035?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Neoantigen-based Personalized Cancer therapeutic Vaccines market Size during the forecast period (by 2035)?
  • At what CAGR, the Neoantigen-based Personalized Cancer therapeutic Vaccines market is expected to grow in 7MM during the forecast period (by 2035)?
  • What would be the Neoantigen-based Personalized Cancer therapeutic Vaccines market outlook across the 7MM during the forecast period (by 2035)?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Neoantigen-based Personalized Cancer therapeutic Vaccines?
  • How many Neoantigen-based Personalized Cancer Therapeutic Vaccines are developed by each company?
  • How many emerging vaccines are in mid-stage, and late-stage of development for the treatment of Neoantigen-based Personalized Cancer therapeutic Vaccines?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Neoantigen-based Personalized Cancer therapeutic Vaccines?
  • What are the recent types, targets, mechanisms of action and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Neoantigen-based Personalized Cancer therapeutic Vaccines and their status?
  • What are the key designations that have been granted to the emerging vaccines?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Neoantigen-based Personalized Cancer therapeutic Vaccines market.
  • To understand the future market competition in the Neoantigen-based Personalized Cancer therapeutic Vaccines market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Neoantigen-based Personalized Cancer therapeutic Vaccines in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Neoantigen-based Personalized Cancer therapeutic Vaccines market.
  • To understand the future market competition in the Neoantigen-based Personalized Cancer therapeutic Vaccines market.

Table of Contents

1. Key Insights

2. Executive Summary of Neoantigen-based Personalized Cancer therapeutic Vaccines

3. Competitive Intelligence Analysis for Neoantigen-based Personalized Cancer therapeutic Vaccines

4. Neoantigen-based Personalized Cancer therapeutic Vaccines: Market Overview at a Glance

  • 4.1. Neoantigen-based Personalized Cancer therapeutic Vaccines-Region Wise Total Market Share (%) Distribution by 2035
  • 4.2. Neoantigen-based Personalized Cancer therapeutic Vaccines-Indication Wise Total Market Share (%) Distribution by 2035

5. Neoantigen-based Personalized Cancer therapeutic Vaccines

  • 5.1. Introduction
    • 5.1.1. Tumor neoantigens: from basic research to clinical applications
    • 5.1.2. Historical overview in the understanding of tumor neoantigens
    • 5.1.3. Neoantigens-directed immunoediting and immune escape
    • 5.1.4. Overview of Preclinical and clinical neoantigen vaccine-based studies
      • 5.1.4.1. Neoantigen-based adoptive T cell transfer
      • 5.1.4.2. Neoantigen-based cancer vaccines
      • 5.1.4.3. Combination of neoantigen vaccine with other therapies
      • 5.1.4.3.1. Biomarker for immune checkpoint inhibitors
      • 5.1.4.3.2. Resistance mechanism for immune checkpoint inhibitors
    • 5.1.5. Identification and prediction of neoantigens
    • 5.1.6. Principle of neoantigen vaccines
    • 5.1.7. Clinical progress
    • 5.1.8. Pros and Cons

6. Unmet Needs

7. Emerging Therapies

  • 7.1. Key Cross Competition
  • 7.2. Tedopi (OSE2101): OSE Immunotherapeutics
    • 7.2.1. Product Description
    • 7.2.2. Other Developmental Activities
    • 7.2.3. Clinical Development
    • 7.2.4. Safety and Efficacy
    • 7.2.5. Product Profile
  • 7.3. GRANITE (GRT-C901) + SLATE (GRT-R902): Gritstone Oncology
    • 7.3.1. Product Description
    • 7.3.2. Other Developmental Activities
    • 7.3.3. Clinical Development
    • 7.3.4. Safety and Efficacy
    • 7.3.5. Product Profile
  • 7.4. GEN-009 Adjuvanted Vaccine: Genocea Biosciences
    • 7.4.1. Product Description
    • 7.4.2. Other Developmental Activities
    • 7.4.3. Clinical Development
    • 7.4.4. Safety and Efficacy
    • 7.4.5. Product Profile
  • 7.5. TG01 Vaccine: Targovax
    • 7.5.1. Product Description
    • 7.5.2. Other Developmental Activities
    • 7.5.3. Clinical Development
    • 7.5.4. Safety and Efficacy
    • 7.5.5. Product Profile
  • 7.6. iNeo-Vac-P01: Hangzhou Neoantigen Therapeutics
    • 7.6.1. Product Description
    • 7.6.2. Other Developmental Activities
    • 7.6.3. Clinical Development
    • 7.6.4. Safety and Efficacy
    • 7.6.5. Product Profile
  • 7.7. NEO-PV-01: Neon Therapeutics
    • 7.7.1. Product Description
    • 7.7.2. Other Developmental Activities
    • 7.7.3. Clinical Development
    • 7.7.4. Safety and Efficacy
    • 7.7.5. Product Profile

List to be continued in report…

8. Neoantigen-based Personalized Cancer therapeutic Vaccines: Seven Major Market Analysis

  • 8.1. Key Findings
  • 8.2. Neoantigen-based Personalized Cancer therapeutic Vaccines Market Size in 7MM

9. 7MM: Market Outlook

  • 9.1. United States: Market Size
    • 9.1.1. Neoantigen-based Personalized Cancer therapeutic Vaccines Total Market Size in the United States
    • 9.1.2. Neoantigen-based Personalized Cancer therapeutic Vaccines Market Size by Therapies in the United States
  • 9.2. EU-5 countries: Market Size and Outlook
    • 9.2.1. Neoantigen-based Personalized Cancer therapeutic Vaccines Total Market Size in EU5 Countries
    • 9.2.2. Neoantigen-based Personalized Cancer therapeutic Vaccines Market Size by Therapies in EU5 Countries
  • 9.3. Japan Market Outlook
    • 9.3.1. Neoantigen-based Personalized Cancer therapeutic Vaccines Total Market Size in Japan
    • 9.3.2. Neoantigen-based Personalized Cancer therapeutic Vaccines Market Size by Therapies in Japan

10. Attribute analysis

11. KOL Views

12. Market Drivers

13. Market Barriers

14. Future Outlook

15. Appendix

  • 15.1. Bibliography
  • 15.2. Report Methodology

16. DelveInsight Capabilities

17. Disclaimer

18. About DelveInsight

List of Tables

  • Table 1: Key Cross - Potential Cancer therapeutic vaccines in 7MM
  • Table 2: Key Cross - Emerging Therapies
  • Table 3: Tedopi, Clinical Trial Description
  • Table 4: GRANITE (GRT-C901) + SLATE (GRT-R902), Clinical Trial Description
  • Table 5: GEN-009 Adjuvanted Vaccine, Clinical Trial Description
  • Table 6: TG01 Vaccine, Clinical Trial Description
  • Table 7: iNeo-Vac-P01, Clinical Trial Description
  • Table 8: NEO-PV-01, Clinical Trial Description
  • Table 9: Assessment of Neoantigen-based Personalized Cancer therapeutic Vaccines based on Major Key Players
  • Table 10: Assessment of Neoantigen-based Personalized Cancer therapeutic Vaccines by Phases
  • Table 11: Assessment of Neoantigen-based Personalized Cancer therapeutic Vaccines by Route of Administration
  • Table 12: Assessment of Neoantigen-based Personalized Cancer therapeutic Vaccines based on Target Indication of the Vaccine
  • Table 13: Market Size of Neoantigen-based Personalized Cancer therapeutic Vaccines - By Indication in the United States by 2035
  • Table 14: Market Size of Neoantigen-based Personalized Cancer therapeutic Vaccines - By Indication in EU5 Countries by 2035
  • Table 15: Market Size of Neoantigen-based Personalized Cancer therapeutic Vaccines - By Indication in Japan Countries by 2035

List of Figures

  • Figure 1: Strategies for Neoantigen-based Personalized Cancer therapeutic Vaccines development
  • Figure 2: Interactions of the immune system with the whole-cell vaccine approach
  • Figure 3: Targeting TSA and TAA
  • Figure 4: Personalized neoantigen peptide vaccine workflow
  • Figure 5: Assessment of Neoantigen-based Personalized Cancer therapeutic Vaccines based on Major Key Players
  • Figure 6: Assessment Neoantigen-based Personalized Cancer therapeutic Vaccines by Phases
  • Figure 7: Assessment of Neoantigen-based Personalized Cancer therapeutic Vaccines by Route of Administration
  • Figure 8: Assessment of Neoantigen-based Personalized Cancer therapeutic Vaccines based on Target Indication of the Vaccine
  • Figure 9: Assessment of Neoantigen-based Personalized Cancer therapeutic Vaccines by Initial Target Indication of Key Players
  • Figure 10: Market Size of Neoantigen-based Personalized Cancer therapeutic Vaccines in the United States, USD Millions by 2035
  • Figure 11: Market Size of Neoantigen-based Personalized Cancer therapeutic Vaccines in EU5 Countries, USD Million by 2035
  • Figure 12: Market Size of Neoantigen-based Personalized Cancer therapeutic Vaccines in Japan, USD Million by 2035
  • Figure 13: Neoantigen-based Personalized Cancer therapeutic Vaccines SWOT Analysis